Centessa Pharmaceuticals PLC

CNTA

Add to Watchlist

39.600USD

-0.010-0.03%

Market hours （ET）Quotes delayed by 15 min

Centessa Pharmaceuticals PLC's Score

Industry at a Glance

Industry Ranking

47 / 383

Overall Ranking

153 / 4490

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Centessa Pharmaceuticals PLC Highlights

StrengthsRisks

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 118.88% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 15.00M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 15.00M.

Undervalued

The company’s latest PE is -22.31, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 150.25M shares, increasing 7.40% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 7.03K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.75.

Analyst Rating

Based on 13 analysts

Hold

Current Rating

44.000

Target Price

+11.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Centessa Pharmaceuticals PLC is 8.37, ranking 38 out of 383 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 203.20%.

Score

Industry at a Glance

Previous score

8.37

Change

0



Financials

6.54

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.53

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.44

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Centessa Pharmaceuticals PLC is 6.80, ranking 210 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -22.31, which is -94.13% below the recent high of -1.31 and -22.42% above the recent low of -27.32.

Score

Industry at a Glance

Previous score

6.80

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/383

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Centessa Pharmaceuticals PLC is 7.54, ranking 290 out of 383 in the Biotechnology & Medical Research industry. The average price target is 36.00, with a high of 52.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

7.54

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Centessa Pharmaceuticals PLC is 5.79, ranking 305 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 39.84 and the support level at 39.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.01

Change

-0.22

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Centessa Pharmaceuticals PLC is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 97.10%, representing a quarter-over-quarter decrease of 2.28%. The largest institutional shareholder is PRFDX, holding a total of 3.93M shares, representing 2.54% of shares outstanding, with 36.53% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Medicxi Ventures (UK) LLP

19.96M

--

Avoro Capital Advisors LLC

14.56M

+34.67%

Adage Capital Management, L.P.

11.28M

+12.42%

Index Ventures SA

9.96M

--

Fidelity Management & Research Company LLC

8.06M

+29.16%

General Atlantic LLC

6.12M

-16.96%

Farallon Capital Management, L.L.C.

5.38M

+24.14%

TCG Crossover Management, LLC

4.29M

+36.67%

Janus Henderson Investors

4.09M

-24.31%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Centessa Pharmaceuticals PLC is 5.10, ranking 53 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 1.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Centessa Pharmaceuticals PLC

CNTA

7.29 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.75 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment